A Phase 1 Double-blind, Randomized, Single Dose, Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
Latest Information Update: 11 Dec 2024
At a glance
- Drugs TB 006 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Acronyms TB006SAD
- Sponsors TrueBinding
Most Recent Events
- 09 Dec 2024 Status changed from recruiting to completed.
- 15 Jun 2021 New trial record